UNSPSC 51112503: Bendamustine

This classification denotes a nitrogen mustard compound with the molecular formula C16H21Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9266D9P3PQ, chemically known as 2-benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochloride but more generally known as bendamustine, which bears US NIH Compound Identifier 65628. Bendamustine most often comes in base and hydrochloride forms.

UNSPSC 51112503 Bendamustine, a Commodity code, encompasses pharmaceutical procurement for cancer treatment agents, though state and local solicitation activity under this specific code is minimal. The Texas Health and Human Services Commission posted a Request for Information (RFI) in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, which signals state-level interest in reshaping how pharmacy benefit programs source oncology drugs and other pharmaceuticals. The RFI targets vendors capable of establishing direct relationships between state agencies and pharmaceutical manufacturers, bypassing traditional pharmacy benefit manager and group purchasing organization intermediaries, with flexibility to negotiate net pricing models and implement outcomes-based agreements.

The source reflects limited recent state and local procurement activity directly tagged to this bendamustine commodity code. The Texas HHS Commission's April 2026 RFI represents exploratory procurement rather than a formal competitive solicitation; it is designed to gather market intelligence on direct-to-manufacturer contracting models before issuing a subsequent RFP. No award value, budget range, set-aside designations, or incumbent information is specified. The RFI deadline has passed, and no follow-on formal solicitation details are present in the source material. This code shows little active competition opportunity at present, and vendors interested in state and local pharmaceutical procurement would benefit from monitoring Texas HHS communications for the anticipated RFP and tracking similar direct-contracting pharmacy initiatives in other states.